Introduction Passive antibody therapy has been used to immunize vulnerable people
against infectious agents. In this study, we aim to investigate the efficacy of convalescent …

Abstract Aim Convalescent Plasma (CP) therapy is of interest as no vaccine or specific
treatment is available for emerging viruses such as severe acute respiratory syndrome …

Objective To study the effectiveness of COVID-19 convalescent plasma (CCP) therapy for
patients with moderate and severe COVID-19 disease. Methods This non-randomized …

Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life
of several hundred thousand worldwide. However, so far no approved vaccine or drug …

There are currently no licensed vaccines or therapeutics for COVID‐19. Anti‐SARS CoV‐2
antibody‐containing plasmas, obtained from the recovered individuals who had confirmed …

Abstract Introduction Coronavirus disease 2019 (COVID-19) is a viral respiratory syndrome
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel virus …

Convalescent plasma (CP) transfusion has been indicated as a promising therapy in the
treatment for other emerging viral infections. However, the quality control of CP and …

BACKGROUND COVID-19 convalescent plasma (CCP) has been considered a treatment
option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing …

Background We assessed outcome of patients with moderate and severe COVID-19
following treatment with convalescent plasma (CP) and the association with IgG levels in …

Currently, there are no approved specific antiviral agents for novel coronavirus disease
2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test …